Publication:
Asociacion de la concentración de homocisteina y dimetil arginina asimetrica y de las variantes alelicas de los genes involucrados en el control de la coagulacion, fibrinolisis y de la presion sanguinea con el riesgo de enfermedad cerebro vascular

Simple item page
dc.contributor.authorCordoba Porras, Alfonso
dc.date.accessioned2023-12-14T20:00:52Z
dc.date.available2023-12-14T20:00:52Z
dc.date.issued2007
dc.description1 documentospa
dc.description.abstractLa homocisteína (Hcy) se forma durante la transformación del aminoácidometionina en otro aminoácido la cisteína . Esta transformación es dependiente dela enzima cistationina ~-sintasa (C~S) y de la vitamina B6 . La Hcy una vez formada puede también transformarse en metionina con la participación de la enzima metionina sintasa, del ácido fólico y de la vitamina B12 . Un número importante de estudios prospectivos y de casos y controles coinciden en señalar que el aumento moderado de la concentración de Hcy ( 16-31 Jlmoles/L) o de dimetilarginina asimétrica (ADMA) en sangre son un factor de riesgo independiente de enfermedad card iovascular. Por otro lado, las alteraciones en los genes que regulan el metabolismo de la Hcy, la fibrinólisis , la coagulación y la presión arterial predisponen a enfermedades cardiovasculares . Se desconoce si el aumento de Hcy o de ADMA en sangre o la presencia de determinados alteraciones genética son factores de riesgo para enfermedad cerebrovascular isquémica (ECVI) en Colombia . Por ello , en este proyecto se estudió la posible asociación de la Hcy , ADMA y de algunas variantes alélicas en los genes que controlan la presión arterial , la coagulación y la fibrinólisis (18 genes) con la ECVI en Colombia .
dc.format.extent57 p.
dc.format.mimetypeapplication/pdf
dc.identifier.urihttps://repositorio.minciencias.gov.co/handle/20.500.14143/50039
dc.language.isospa
dc.publisherUniversidad de Antioquia
dc.publisherColciencias
dc.publisher.placeMedellín
dc.rights.accessrightsinfo:eu-repo/semantics/openAccess
dc.rights.creativecommonsAtribución 4.0 Internacional (CC BY 4.0)
dc.rights.urihttps://creativecommons.org/licenses/by/4.0/
dc.subject.armarcEnfermedades del cerebro
dc.subject.lembProyectos de investigación
dc.subject.proposalCoagulaciónspa
dc.subject.proposalEnfermedades del cerebrospa
dc.subject.proposalEnfermedades vascularesspa
dc.subject.proposalHomocisteínaspa
dc.titleAsociacion de la concentración de homocisteina y dimetil arginina asimetrica y de las variantes alelicas de los genes involucrados en el control de la coagulacion, fibrinolisis y de la presion sanguinea con el riesgo de enfermedad cerebro vascularspa
dc.typeInforme de investigación
dc.type.coarhttp://purl.org/coar/resource_type/c_18ws
dc.type.contentText
dc.type.driverinfo:eu-repo/semantics/report
dc.type.redcolhttp://purl.org/redcol/resource_type/INF
dc.type.versioninfo:eu-repo/semantics/publishedVersion
dcterms.audienceEstudiantes, Profesores, Comunidad científica colombiana, etc.,
dcterms.referencesMurray CJ, Lopez AD . Mortality by cause for eight regions of the world : Global Burden of Disease Study. Lancet 1997;349(9061 ): 1269- 76
dcterms.referencesMurray CJ, Lopez AD . Global mortality, disability, and the contribution of risk factors: Global Burden of Disease Study . Lancet 1997;349(9063): 1436-42
dcterms.referencesHankey GJ . Stroke : how large a public health problem , and how can the neurologist help? Arch Neurol1999;56(6):748-54
dcterms.referencesWhisnant JP. Modeling of risk factors for ischemic stroke. The Willis Lecture . Stroke . 1997 ;28(9) : 1840-4.
dcterms.referencesHankey GJ, Eikelboom JW. Homocysteine and vascular disease . Lancet 1999;354(9176) :407-13.
dcterms.referencesRidker PM., Miletich JP., Hennekens CH . , et al. Ethnic distribution of factor V leiden in 4047 men and women. lmplications for venous thromboemolism screening . JAMA. 1997. 277 . 1305-1307.
dcterms.referencesPoort SR, Rosendaal FR. , Reitsma PH, et al. A common geneic variant in the 3' untraslated region of the prothrombin gene is associated with elevated plasma prothrombin levels and an increase in venous thromboisis . Blood. 1996. 88. 3698-3703 .
dcterms.referencesMartiskainen M., Pohjasvaara T., Mikkelsson J. , et al. Fibrinogen gene prometer -455 A Allele as a risk factor for lacunar Stroke . Stroke. 2003. 34. 886-891 .
dcterms.referencesMartiskainen M., Pohjasvaara T., Mikkelsson J. , et al. Fibrinogen gene prometer -455 A Allele as a risk factor for lacunar Stroke . Stroke. 2003. 34. 886-891 .
dcterms.referencesCallen D. the plasminogen (fibrinolytio) system . Thromb. Haemost. 1999. 82. 259-270 .
dcterms.referencesYe S., S. Dhillon , L. Dunleavey, et al. Epistatic interaction between variations in the renin angiotensin 1 converting enzyme and angiotensin 11 type 1 receptor genes in relation to extent of coronary atherosclerosis. Heart . 2003. 89 . 1195-1199
dcterms.referencesSato Noriyuki, tomohiro Katsuya, Tsutomu Nakagawa, et al. Nine polymorphism of angiotensinogen gene in the susceptibility to esencial hypertension . Lite sciences . 2000 . 68 . 259-272.
dcterms.referencesNiu Tianhua , Jianhua Yang , Binyan Wang , et al. Angiotensinogen Gene polymorphism M235T/T174M . No excess transmission to hypertensive Chinese . Hypertension . 33 . 698-702.
dcterms.referencesBuraczynska Monika, Zbigniew Pijanowski, Danuta Spasiewicz, et al. Renin angiotensin gene polymorphisms: assessment of the risk of coronary heart disease . Polish heart journal. 2003. 58. 1. 1-5 .
dcterms.referencesMiller J, Thai K, Scholey J. Angotensin 11 type receptor gene polymorphism and the response to hyperglycaemia in early type 1 diabetes. Diabetes . 2000. 49. 1585-1589.
dcterms.referencesHautanena A., Lankinen L., Kupari M., et al. Association between aldosterone synthase gene polymorphism and the adrenocortical function in males . Journal of international Medicine . 1998. 244 . 11-18.
dcterms.referencesNasreen Shampa , Toru Nabika , Hiroshi Shibata et al. T-786C polymorphism in endotelial No synthase gene affects cerebral circulation in smokers: posible gene-environmental interaction . Artherioscler. Thromb. Vasc. Biol. 2002. 22 605-610.
dcterms.referencesMandel H., Brenner B. , Berant M. , et al. Coexistence of hereditary homocysteinuria and factor V leiden-effect on thrombosis. N. Engl. J. Med. 1996. 334. 763-768
dcterms.referencesGiafranco Sebastio, Maria Pia Sperandeo, michele Panico, et al. The molecula basis of homocystinuria due to cystathionine p synthase deficiency in ltalian Families, and report of four novel mutations . Am. J. Hum . Genet. 1995 . 56. 1324-1333.
dcterms.referencesUrreizti Roser, Susana balcells, marga Rodes, Laura Vilarinho, et al. Spectrum of CBS mutations in 16 homocystinuric patients from lberian península: high prevalence of T191 M and absence of 1278T or G307S. Human mutation in brief. 2003 . 624 .
dcterms.referencesMcCully KS. Homocysteine and vascular disease.Nat Med. 1996;4 :386-9.
dcterms.referencesTan NC, Venketasubramanian N, Saw SM , Tjia HT. Hyperhomocyst(e)inemia and risk of ischemic stroke among young Asian adults. Stroke 2002 ;33(8): 1956-62
dcterms.referencesEikelboom . JW, Hankey GJ, Anand SS, Lofthouse E, Staples N, Baker Rl. Association between high homocyst(e)ine and ischemic stroke dueto large- and small-artery disease but not other etiologic subtypes of ischemic stroke . Stroke 2000;31(5):1069-75.|
dcterms.referencesVerhoef P, Hennekens CH, Malinow MR, Kok FJ , Willett WC , Stampfer MJ . A prospective study of plasma homocyst(e)ine and risk of ischemic stroke . Stroke 1994;25(1 O) : 1924-30.
dcterms.referencesKristensen B, Malm J, Nilsson TK, Hultdin J, Carlberg B, Dahlen G et al. Hyperhomocysteinemia and hypofibrinolysis in young adults with ischemic stroke. Stroke 1999 ; 30(5):974-980.
dcterms.references. Bots ML , Launer LJ , Lindemans J, Hoes AW, Hofman A , Witteman JC, et al. Homocysteine and short-term risk of myocardial infarction and stroke in the· elderly : the Rotterdam Study. Arch lntern Med 1999 ; 159(1 ) :38-44
dcterms.referencesBostom AG, Rosenberg IH, Silbershatz H, Jacques PF, Selhub J, D'Agostino RB, et al. Nonfasting plasma total homocysteine levels and stroke incidence in elderly persons: the Framingham Study. Ann lntern Med 1999 ; 131(5) :352-5
dcterms.referencesKittner SJ, Giles WH, Macko RF , Hebel JR, Wozniak MA, Wityk RJ, et al. Homocyst(e)ine and risk of cerebral infarction in a biracial population : the stroke prevention in young women study . Stroke 1999 ;30(8) : 1554-60
dcterms.referencesMalinow MR , Bostom AG, Krauss RM. Homocyst(e)ine, diet, and cardiovascular diseases: a statement for healthcare professionals from the Nutrition Committee, American Heart Association. Circulation 1999;99(1 ): 178-82.
dcterms.referencesLindgren A, Brattstrom L, Norrving B, Hultberg B, Andersson A, Johansson BB . Plasma homocysteine in the acute and convalescent phases after stroke. Stroke 1995 ; 26(5):795-800
dcterms.referencesCoull BM , Malinow MR, Beamer N, Sexton G, Nordt F, de GP . Elevated plasma homocyst(e)ine concentration as a possible independent risk factor for stroke . Stroke 1990 ; 21 (4):572-576
dcterms.referencesNygard O , Nordrehaug JE, Refsum H, Ueland PM , Farstad M , Vollset SE. Plasma homocysteine levels and mortality in patients with coronary artery disease. N Engl J Med 1997;337(4):230-6
dcterms.referencesBoysen G, Brander T, ehristensen H, Gideon R, Truelsen T. Homocysteine and risk of recurrent stroke. Stroke 2003 ; 34(5): 1256- 1261.
dcterms.referencesdel Ser T, Barba R, Herranz AS , Seijas V, Lopez-Manglano e , Domingo J et al. Hyperhomocyst(e)inemia is a risk factor of secondary vascular events in stroke patients . eerebrovasc Dis 2001 ; 12(2): 91-98 .
dcterms.referencesLenzen H, Tsikas D, Boger RH : Asymmetric dimethylarginine (ADMA) and the risk for coronary heart disease: the multicenter eAR.DIAe study. Eur J elin Pharmacol , 2006, 62, Suppl 13, 45-49.
dcterms.referencesWanby P, Teerlink T, Brudin L, Brattstrom L,Nilsson 1, Palmqvist P , earlsson M: Asymmetric dimethylarginine (ADMA) as a risk marker for stroke and TIA in a Swedish population . Atherosclerosis, 2006, 185 , 271-277.
dcterms.referencesYoo JH and Lee Se Elevated levels of plasma homocyst(e)ine and asymmetric dimethylarginine in elderly patients with stroke. Atherosclerosis. 2001; 158(2):425-30.
dcterms.referencesHaider DG , Bucek RA , Reiter M, Minar E, Hron G, Kyrle PA, Mittermayer F, Wolzt M. The cardiovascular risk marker asymmetrical dimethylarginine is not affected by venous thromboembolism. Transl Res . 2006;48(1):26-9.
dspace.entity.typePublication
oaire.accessrightshttp://purl.org/coar/access_right/c_abf2
oaire.awardnumber11150416471
oaire.awardtitleAsociacion de la concentración de homocisteina y dimetil arginina asimetrica y de las variantes alelicas de los genes involucrados en el control de la coagulacion, fibrinolisis y de la presion sanguinea con el riesgo de enfermedad cerebro vascular.
oaire.funderidentifier.colciencias11150416471
oaire.versionhttp://purl.org/coar/version/c_970fb48d4fbd8a85

Files

Original bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
1115-04-16-471.pdf
Size:
23.99 MB
Format:
Adobe Portable Document Format
Download
License bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
license.txt
Size:
15.18 KB
Format:
Item-specific license agreed upon to submission
Description:
Download

Collections

Informes Finales de Proyectos de Investigación